Brokers Set Expectations for ABVC BioPharma, Inc.’s Q2 2022 Earnings (OTCMKTS:ABVC)
ABVC BioPharma, Inc. (OTCMKTS:ABVC – Get Rating) – Investment analysts at Zacks Investment Research issued their Q2 2022 earnings per share (EPS) estimates for ABVC BioPharma in a research note issued to investors on Tuesday, June 7th. Zacks Investment Research analyst M. Marin forecasts that the company will post earnings of ($0.20) per share for the quarter. Zacks Investment Research also issued estimates for ABVC BioPharma’s Q3 2022 earnings at ($0.21) EPS and Q4 2022 earnings at ($0.21) EPS.
ABVC BioPharma (OTCMKTS:ABVC – Get Rating) last released its quarterly earnings results on Thursday, March 31st. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.27). The firm had revenue of ($0.04) million for the quarter, compared to the consensus estimate of $0.19 million. ABVC BioPharma had a negative net margin of 2,145.77% and a negative return on equity of 287.25%.
Shares of OTCMKTS:ABVC opened at $1.91 on Thursday. The stock has a 50 day moving average of $2.34 and a 200 day moving average of $2.69. ABVC BioPharma has a 12-month low of $1.83 and a 12-month high of $11.69.
Large investors have recently made changes to their positions in the stock. Credit Suisse AG purchased a new stake in shares of ABVC BioPharma during the 3rd quarter worth approximately $27,000. Squarepoint Ops LLC purchased a new stake in ABVC BioPharma during the 3rd quarter valued at $44,000. Virtu Financial LLC raised its holdings in ABVC BioPharma by 95.9% during the 4th quarter. Virtu Financial LLC now owns 27,221 shares of the company’s stock valued at $92,000 after buying an additional 13,329 shares during the period. Finally, Geode Capital Management LLC purchased a new stake in ABVC BioPharma during the 3rd quarter valued at $115,000. Institutional investors own 1.61% of the company’s stock.
About ABVC BioPharma (Get Rating)
ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage.
Receive News & Ratings for ABVC BioPharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ABVC BioPharma and related companies with MarketBeat.com’s FREE daily email newsletter.